197 related articles for article (PubMed ID: 29055450)
1. Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis.
Šega-Jazbec S; Barun B; Horvat Ledinek A; Fabekovac V; Krbot Skorić M; Habek M
Mult Scler Relat Disord; 2017 Oct; 17():151-153. PubMed ID: 29055450
[TBL] [Abstract][Full Text] [Related]
2. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
3. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
[TBL] [Abstract][Full Text] [Related]
4. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol.
Conte WL; Arndt N; Cipriani VP; Dellaria A; Javed A
Mult Scler Relat Disord; 2019 Jan; 27():397-399. PubMed ID: 30508784
[TBL] [Abstract][Full Text] [Related]
5. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Perumal JS; Foo F; Cook P; Khan O
Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
[TBL] [Abstract][Full Text] [Related]
7. Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program.
Caon C; Namey M; Meyer C; Mayer L; Oyuela P; Margolin DH; Rizzo M
Int J MS Care; 2015; 17(4):191-8. PubMed ID: 26300705
[TBL] [Abstract][Full Text] [Related]
8. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
9. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Cuker A; Bass AD; Nadj C; Agius MA; Steingo B; Selmaj KW; Thoits T; Guerreiro A; Van Wijmeersch B; Ziemssen T; Meuth SG; LaGanke CC; Thangavelu K; Rodriguez CE; Baker DP; Margolin DH; Jannsens A
Mult Scler; 2020 Jan; 26(1):48-56. PubMed ID: 30785358
[TBL] [Abstract][Full Text] [Related]
10. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
Ahrabian D; Neill L; Bell R; Leary SM
Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
[TBL] [Abstract][Full Text] [Related]
11. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
Holmøy T; Fevang B; Olsen DB; Spigset O; Bø L
BMC Res Notes; 2019 Aug; 12(1):497. PubMed ID: 31405369
[TBL] [Abstract][Full Text] [Related]
12. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Kocsik AS; Klein DE; Liedke M; Kaunzner UW; Nealon NM; Gauthier SA; Vartanian T; Perumal JS
J Neurol; 2018 May; 265(5):1226-1229. PubMed ID: 29666985
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
Frau J; Coghe G; Lorefice L; Fenu G; Musu L; Cocco E
J Neurol; 2019 Jun; 266(6):1405-1411. PubMed ID: 30863891
[TBL] [Abstract][Full Text] [Related]
14. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
15. Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
Notas K; Papadaki E; Orologas A; Moschou M; Kimiskidis VK
Mult Scler Relat Disord; 2020 Feb; 38():101517. PubMed ID: 31751858
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
18. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
19. A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab.
Räuber S; Pawlitzki M; Korsen M; Kullmann JS; Thoene D; Pfeuffer S; Rolfes L; Nelke C; Melzer N; Ruck T; Meuth SG;
Mult Scler Relat Disord; 2022 Mar; 59():103670. PubMed ID: 35150978
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
